TransMedics Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer
October 29, 2024 6:04 AM EDTOppenheimer analyst Suraj Kalia lowered the price target on TransMedics Group (NASDAQ: TMDX) to $125.00 (from $200.00) while maintaining a Outperform rating.
The analyst comments "TransMedics reported 3Q24 revs. of $108.8M, below our/consensus $117.1M/$115.0M estimates. In Q3, our calculated US transplant shares were 21%/27%/4%... More
TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance
October 28, 2024 4:11 PM EDTTransMedics Group (NASDAQ: TMDX) reported Q3 EPS of $0.12, $0.17 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $114.99 million.
GUIDANCE:
TransMedics Group sees FY2024 revenue of $425-445 million, versus the consensus of... More
